Patient Reported Outcomes Burdens and Experiences (PROBE) - Phase 3 - Longitudinal Data Collection View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2018-2026

ABSTRACT

The PROBE Phase-3 study will collect data on patient reported outcomes, burdens, and experiences in patients living with hemophilia. The investigators will perform comparisons among countries, within country over time, within country against national normative data. Detailed Description BACKGROUND The PROBE questionnaire is a tool for the assessment of patient-reported outcome, burdens and experiences. Until now, it has been used in persons living with hemophilia (PWH) and healthy controls. In phase 1 of the study, the investigators developed the questionnaire. In phase 2 of the study, the investigators evaluated the reliability, reproducibility, responsiveness, and costs of PROBE. The tool has been tested across 21 countries and it has been shown that PROBE is a valid questionnaire for the evaluation of patient reported outcomes (PROs) in PWH and control populations. The questionnaire is available in 11 languages (with 20 localized versions worldwide), and another 17 languages and 45 more localizations are in the process of development. CURRENT STUDY and FUTURE DIRECTIONS Phase 3 is the natural prosecution of the project. In this phase, the investigators aim at maintaining the capacity to collect data on PROBE, and the infrastructure will also be modified in order to allow for longitudinal collection of PROBE data (in previous phases, the investigators only collected anonymized data). The objective of the study is to compare data on PROBE between countries, within-countries over time, and within-countries against national normative data. Reports will be produced every 2 years. Data collected during phase 2 of the study will also be used. At the same time, the research framework will have the potential for: - Expanding country participation within existing and new regions. - Integrating the PROBE questionnaire in clinical trials, longitudinal studies, health technology assessment studies, routine clinical care, and registries. - Using PROBE in new countries - Testing the performance of the PROBE questionnaire in new patient populations INVESTIGATION TEAM Principal Investigator: 1. Mark Skinner JD, Institute for Policy Advancement Ltd. (US) Co-Investigators: 2. Alfonso Iorio MD Ph.D. FRCPC, McMaster University, Department of Clinical Epidemiology and Biostatistics (Canada) 3. Randall Curtis MBA, Factor VIII Computing (US) 4. Neil Frick MS, National Hemophilia Foundation (US) 5. Michael Nichol Ph.D., University of Southern California, School of Policy and Planning Development (US) 6. Declan Noone, Irish Hemophilia Society (Ireland) 7. David Page, Canadian Hemophilia Society (Canada) 8. Jeff Stonebraker Ph.D., North Carolina State University Poole College of Management (US) 9. Brian O'Mahoney, Irish Hemophilia Society (Ireland) 10. Chatree Chai-Adisaksopha, MD MSc. More... »

URL

https://clinicaltrials.gov/show/NCT03549858

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3177", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The PROBE Phase-3 study will collect data on patient reported outcomes, burdens, and experiences in patients living with hemophilia. The investigators will perform comparisons among countries, within country over time, within country against national normative data.\n\nDetailed Description\nBACKGROUND The PROBE questionnaire is a tool for the assessment of patient-reported outcome, burdens and experiences. Until now, it has been used in persons living with hemophilia (PWH) and healthy controls. In phase 1 of the study, the investigators developed the questionnaire. In phase 2 of the study, the investigators evaluated the reliability, reproducibility, responsiveness, and costs of PROBE. The tool has been tested across 21 countries and it has been shown that PROBE is a valid questionnaire for the evaluation of patient reported outcomes (PROs) in PWH and control populations. The questionnaire is available in 11 languages (with 20 localized versions worldwide), and another 17 languages and 45 more localizations are in the process of development. CURRENT STUDY and FUTURE DIRECTIONS Phase 3 is the natural prosecution of the project. In this phase, the investigators aim at maintaining the capacity to collect data on PROBE, and the infrastructure will also be modified in order to allow for longitudinal collection of PROBE data (in previous phases, the investigators only collected anonymized data). The objective of the study is to compare data on PROBE between countries, within-countries over time, and within-countries against national normative data. Reports will be produced every 2 years. Data collected during phase 2 of the study will also be used. At the same time, the research framework will have the potential for: - Expanding country participation within existing and new regions. - Integrating the PROBE questionnaire in clinical trials, longitudinal studies, health technology assessment studies, routine clinical care, and registries. - Using PROBE in new countries - Testing the performance of the PROBE questionnaire in new patient populations INVESTIGATION TEAM Principal Investigator: 1. Mark Skinner JD, Institute for Policy Advancement Ltd. (US) Co-Investigators: 2. Alfonso Iorio MD Ph.D. FRCPC, McMaster University, Department of Clinical Epidemiology and Biostatistics (Canada) 3. Randall Curtis MBA, Factor VIII Computing (US) 4. Neil Frick MS, National Hemophilia Foundation (US) 5. Michael Nichol Ph.D., University of Southern California, School of Policy and Planning Development (US) 6. Declan Noone, Irish Hemophilia Society (Ireland) 7. David Page, Canadian Hemophilia Society (Canada) 8. Jeff Stonebraker Ph.D., North Carolina State University Poole College of Management (US) 9. Brian O'Mahoney, Irish Hemophilia Society (Ireland) 10. Chatree Chai-Adisaksopha, MD MSc.", 
    "endDate": "2026-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03549858", 
    "keywords": [
      "patient outcome", 
      "patient-reported outcome", 
      "phase 3", 
      "longitudinal data collection", 
      "burden", 
      "patient", 
      "Hemophilia A", 
      "comparison", 
      "country", 
      "normative data", 
      "questionnaire", 
      "tool", 
      "assessment", 
      "Living", 
      "healthy control", 
      "Phase 1", 
      "Phase 2", 
      "Reproducibility of Result", 
      "reproducibility", 
      "responsiveness", 
      "Evaluation Study as Topic", 
      "control population", 
      "language", 
      "worldwide", 
      "localization", 
      "development", 
      "future direction", 
      "prosecution", 
      "investigator aim", 
      "capacity", 
      "infrastructure", 
      "collection", 
      "previous phase", 
      "anonymized data", 
      "same time", 
      "research framework", 
      "participation", 
      "clinical trial", 
      "longitudinal study", 
      "health technology assessment", 
      "routine clinical care", 
      "registry", 
      "patient population", 
      "principal investigator", 
      "advancement", 
      "US", 
      "co-investigators", 
      "MD", 
      "d.s", 
      "McMaster University", 
      "Clinical Epidemiology and Biostatistics", 
      "Canada", 
      "Curtis", 
      "factor VIII", 
      "foundation", 
      "Michael", 
      "University of Southern California", 
      "policy planning", 
      "society", 
      "Ireland", 
      "David", 
      "canadian", 
      "PHS", 
      "North Carolina State University", 
      "Brian", 
      "MSc"
    ], 
    "name": "Patient Reported Outcomes Burdens and Experiences (PROBE) - Phase 3 - Longitudinal Data Collection", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03549858"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00027.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.422264.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.25073.33", 
        "type": "Organization"
      }
    ], 
    "startDate": "2018-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/s40814-018-0253-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101229089", 
          "https://doi.org/10.1186/s40814-018-0253-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40814-018-0253-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101229089", 
          "https://doi.org/10.1186/s40814-018-0253-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03549858"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03549858'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03549858'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03549858'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03549858'


 

This table displays all metadata directly associated to this object as RDF triples.

91 TRIPLES      16 PREDICATES      83 URIs      75 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03549858 schema:about anzsrc-for:3177
2 schema:description The PROBE Phase-3 study will collect data on patient reported outcomes, burdens, and experiences in patients living with hemophilia. The investigators will perform comparisons among countries, within country over time, within country against national normative data. Detailed Description BACKGROUND The PROBE questionnaire is a tool for the assessment of patient-reported outcome, burdens and experiences. Until now, it has been used in persons living with hemophilia (PWH) and healthy controls. In phase 1 of the study, the investigators developed the questionnaire. In phase 2 of the study, the investigators evaluated the reliability, reproducibility, responsiveness, and costs of PROBE. The tool has been tested across 21 countries and it has been shown that PROBE is a valid questionnaire for the evaluation of patient reported outcomes (PROs) in PWH and control populations. The questionnaire is available in 11 languages (with 20 localized versions worldwide), and another 17 languages and 45 more localizations are in the process of development. CURRENT STUDY and FUTURE DIRECTIONS Phase 3 is the natural prosecution of the project. In this phase, the investigators aim at maintaining the capacity to collect data on PROBE, and the infrastructure will also be modified in order to allow for longitudinal collection of PROBE data (in previous phases, the investigators only collected anonymized data). The objective of the study is to compare data on PROBE between countries, within-countries over time, and within-countries against national normative data. Reports will be produced every 2 years. Data collected during phase 2 of the study will also be used. At the same time, the research framework will have the potential for: - Expanding country participation within existing and new regions. - Integrating the PROBE questionnaire in clinical trials, longitudinal studies, health technology assessment studies, routine clinical care, and registries. - Using PROBE in new countries - Testing the performance of the PROBE questionnaire in new patient populations INVESTIGATION TEAM Principal Investigator: 1. Mark Skinner JD, Institute for Policy Advancement Ltd. (US) Co-Investigators: 2. Alfonso Iorio MD Ph.D. FRCPC, McMaster University, Department of Clinical Epidemiology and Biostatistics (Canada) 3. Randall Curtis MBA, Factor VIII Computing (US) 4. Neil Frick MS, National Hemophilia Foundation (US) 5. Michael Nichol Ph.D., University of Southern California, School of Policy and Planning Development (US) 6. Declan Noone, Irish Hemophilia Society (Ireland) 7. David Page, Canadian Hemophilia Society (Canada) 8. Jeff Stonebraker Ph.D., North Carolina State University Poole College of Management (US) 9. Brian O'Mahoney, Irish Hemophilia Society (Ireland) 10. Chatree Chai-Adisaksopha, MD MSc.
3 schema:endDate 2026-12-01T00:00:00Z
4 schema:keywords Brian
5 Canada
6 Clinical Epidemiology and Biostatistics
7 Curtis
8 David
9 Evaluation Study as Topic
10 Hemophilia A
11 Ireland
12 Living
13 MD
14 MSc
15 McMaster University
16 Michael
17 North Carolina State University
18 PHS
19 Phase 1
20 Phase 2
21 Reproducibility of Result
22 US
23 University of Southern California
24 advancement
25 anonymized data
26 assessment
27 burden
28 canadian
29 capacity
30 clinical trial
31 co-investigators
32 collection
33 comparison
34 control population
35 country
36 d.s
37 development
38 factor VIII
39 foundation
40 future direction
41 health technology assessment
42 healthy control
43 infrastructure
44 investigator aim
45 language
46 localization
47 longitudinal data collection
48 longitudinal study
49 normative data
50 participation
51 patient
52 patient outcome
53 patient population
54 patient-reported outcome
55 phase 3
56 policy planning
57 previous phase
58 principal investigator
59 prosecution
60 questionnaire
61 registry
62 reproducibility
63 research framework
64 responsiveness
65 routine clinical care
66 same time
67 society
68 tool
69 worldwide
70 schema:name Patient Reported Outcomes Burdens and Experiences (PROBE) - Phase 3 - Longitudinal Data Collection
71 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03549858
72 schema:sdDatePublished 2019-03-07T15:27
73 schema:sdLicense https://scigraph.springernature.com/explorer/license/
74 schema:sdPublisher Ndb330788b29f4d51be7af4de8c0b1342
75 schema:sponsor https://www.grid.ac/institutes/grid.25073.33
76 https://www.grid.ac/institutes/grid.422264.4
77 schema:startDate 2018-01-01T00:00:00Z
78 schema:subjectOf sg:pub.10.1186/s40814-018-0253-0
79 schema:url https://clinicaltrials.gov/show/NCT03549858
80 sgo:license sg:explorer/license/
81 sgo:sdDataset clinical_trials
82 rdf:type schema:MedicalStudy
83 Ndb330788b29f4d51be7af4de8c0b1342 schema:name Springer Nature - SN SciGraph project
84 rdf:type schema:Organization
85 anzsrc-for:3177 schema:inDefinedTermSet anzsrc-for:
86 rdf:type schema:DefinedTerm
87 sg:pub.10.1186/s40814-018-0253-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101229089
88 https://doi.org/10.1186/s40814-018-0253-0
89 rdf:type schema:CreativeWork
90 https://www.grid.ac/institutes/grid.25073.33 schema:Organization
91 https://www.grid.ac/institutes/grid.422264.4 schema:Organization
 




Preview window. Press ESC to close (or click here)


...